Storia in 4 fonti

Datroway nabs FDA approval for immunotherapy-ineligible triple-negative breast cancer

The FDA approved datopotamab deruxtecan-dlnk as the first TROP2-directed antibody drug conjugate for first-line treatment of unresectable or metastatic triple-negative breast cancer in patients ineligible for PD-1/PD-L1 inhibitor therapy.The agency granted priority review and approved datopotamab deruxtecan (Datroway; AstraZeneca, Daiichi Sankyo) based on results from the phase 3 TROPION-Breast02

Raccontata da

venerdì 22 maggio 2026·healio.com
Datroway nabs FDA approval for immunotherapy-ineligible triple-negative breast cancer
The FDA approved datopotamab deruxtecan-dlnk as the first TROP2-directed antibody drug conjugate for first-line treatment of unresectable or metastatic triple-negative breast…
venerdì 22 maggio 2026·morningstar.com
Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple…
Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not…

Datroway nabs FDA approval for immunotherapy-ineligible triple-negative breast cancer

Datroway nabs FDA approval for immunotherapy-ineligible triple-negative breast cancer

Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple…

FDA grants Daiichi Sankyo and AstraZeneca’s Datroway a key breast cancer approval

AstraZeneca, Daiichi beat Gilead to first-line TNBC with FDA nod for Datroway